Reccan (former Pharma4Cure) aims to develop improved diagnosis and targeted, tumour-specific treatment of solid cancer. The focus area has been pancreatic cancer, but findings suggest suitability for several other diagnosis groups. The identification of biomarkers in blood and tissue is the basis for the development work. The researchers have worked on identifying unique proteins and protein fragments through a blood test to diagnose the disease’s various stages. This could be used as screening for those who are in the risk group, as well as help to direct the choice of treatment.
Roland Anderson and Daniel Ansari, researchers at Lund University, are involved in clinical and preclinical work on pancreatic cancer. Together with protein researcher, György Marko-Varga, who is also active at Lund University, they are the founders of Reccan Diagnostics.
Develops enhanced diagnostic tools and targeted, tumour-specific therapies against solid cancers.
Founded by Roland Andersson, Daniel Ansari and György Marko-Varga.
Portfolio company since 2015.
Portfolio Manager LU Holding:
christine [dot] widstrand [at] innovation [dot] lu [dot] se (Christine Widstrand), phone +46 70 928 63 78